Specifically, we proposed to add a new paragraph (c)(3) to 425.316 to recognize that, for performance years beginning on or after January 1, 2026, if an ACO fails to meet both the quality performance standard and the alternative quality performance standard, as determined at 425.512, CMS may take one or more of the actions prior to termination specified at 425.216
Unfortunately, as we grow older, our endogenous glutathione production declines, compromising our antioxidant defenses and leaving us vulnerable to the ravages of free-radicals
Once commercially available (expected late 2026-2027), brand-name retatrutide pricing will likely mirror or exceed tirzepatide pricing, given Eli Lilly manufactures both compounds and the market dynamics of premium obesity medications
Securing your spot for specialized care is a hassle-free and patient-friendly process